STOCK TITAN

Novartis Capital issues $1.75B notes due 2037

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Novartis AG filed transaction documents for incorporation into its Form F-3 registration statement in connection with Novartis Capital Corporation’s issuance of four note tranches: $500 million of 4.900% notes due 2029, $1.5 billion of 5.200% notes due 2032, $1.75 billion of 5.300% notes due 2034, and $1.75 billion of 5.500% notes due 2037. The materials include a terms agreement, forms of Guaranteed Debt Security for each tranche, an officer’s certificate, legal opinions and consents.

2029 Notes aggregate principal amount $500 million 4.900% Notes due 2029
2029 Notes coupon 4.900% Notes due 2029
2032 Notes aggregate principal amount $1.5 billion 5.200% Notes due 2032
2032 Notes coupon 5.200% Notes due 2032
2034 Notes aggregate principal amount $1.75 billion 5.300% Notes due 2034
2034 Notes coupon 5.300% Notes due 2034
2037 Notes aggregate principal amount $1.75 billion 5.500% Notes due 2037
2037 Notes coupon 5.500% Notes due 2037
aggregate principal amount financial
"$500,000,000 aggregate principal amount of 4.900% Notes due 2029"
The aggregate principal amount is the total amount of money borrowed through a bond or loan that the borrower promises to repay. It’s like the original price tag on a loan or bond, showing how much money is involved in the deal. This number matters because it indicates the size of the debt and helps investors understand the scale of the borrowing.
Terms Agreement financial
"Terms Agreement, dated November 9, 2026"
Guaranteed Debt Security financial
"Form of Guaranteed Debt Security for the 2029 Notes"
Form F-3 regulatory
"Registration Statement on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What notes did Novartis Capital Corporation issue for NVS?

Novartis Capital Corporation’s notes comprise $500 million of 4.900% notes due 2029, $1.5 billion of 5.200% notes due 2032, $1.75 billion of 5.300% notes due 2034, and $1.75 billion of 5.500% notes due 2037.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

Report on Form 6-K dated November 12, 2026
(Commission File No. 1-15024)

 

Novartis AG

(Name of Registrant)

 

Lichtstrasse 35

4056 Basel
Switzerland

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F: x    Form 40-F: ¨

 

 

 

 
 

 

EXPLANATORY NOTE

 

In connection with the issuance by Novartis Capital Corporation of $500,000,000 aggregate principal amount of 4.900% Notes due 2029 (the “2029 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2032 (the “2032 Notes”), $1,750,000,000 aggregate principal amount of 5.300% Notes due 2034 (the “2034 Notes”) and $1,750,000,000 aggregate principal amount of 5.500% Notes due 2037 (the “2037 Notes”), Novartis AG is filing the following documents solely for incorporation into the Registration Statement on Form F-3 (File Nos. 333-282133 and 333-282133-01).

 

Exhibits:

 

1.1 Terms Agreement, dated November 9, 2026, among Novartis AG, Novartis Capital Corporation and Barclays Capital Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC and SG Americas Securities, LLC, as representatives of the several underwriters named therein
4.1 Form of Guaranteed Debt Security for the 2029 Notes
4.2 Form of Guaranteed Debt Security for the 2032 Notes
4.3 Form of Guaranteed Debt Security for the 2034 Notes
4.4 Form of Guaranteed Debt Security for the 2037 Notes
4.5 Officer’s Certificate of Novartis Capital Corporation
5.1 Opinion of Davis Polk & Wardwell LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation
5.2 Opinion of Advestra AG, special Swiss counsel to Novartis AG
23.1 Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
23.2 Consent of Advestra AG (included in Exhibit 5.2)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date:  November 12, 2026   Novartis AG
     
      By: /s/ Daniel Weiss
        Name: Daniel Weiss
        Title: Authorized Signatory

 

 

 

 

Filing Exhibits & Attachments

8 documents

Keep reading